Factors Associated With Bone Density Monitoring While on Antiosteoporosis Treatment in Routine Clinical Practice: A Registry-Based Cohort Study

Long Non-Coding RNA Metastasis Associated Lung Adenocarcinoma Transcript 1 (LncRNA MALAT1) Shuttling Through Exosome from Bone Marrow Mesenchymal Stem Cell (BMSC) Regulates the Differentiation of Osteoblast in Osteoporosis Rats

This study assesses the effect of LncRNA MALAT1 on osteoblast differentiation in OP rats. The BMSC were transfected with LncRNA MALAT1. The OP rats’ model was established and then assigned into NC set, OP set, BMSC set, BMSCs/LncRNA-NC set and BMSCs/LncRNA MALAT1 set followed by analysis of LncRNA MALAT1, microRNA-34 and cSATB2 expression by RT-PCR, and Bax, Caspase-3 and ALP level in exosome by Western Blot assy. The protein expression of Bax and Caspase-3 in OP set was significantly increased compared with NC set but reduced in BMSCs/LncRNA MALAT1 set without significant differences between BMSC set and BMSC/NC set. There was orderly array of collagenous fiber in lamellar bone of NC set. The quantity of bone lacuna was moderate with orderly array of bone trabecula. There was disorderly array of collagenous fiber in lamellar bone of model set. There were a large number of distribution of osteoblast in the breakdown area with the dissolution of periosteum. The protein level of Bax and Caspase-3 was reduced by LncRNA MALAT1 from BMSC and the level of ALP, microRNA-34 and cSATB2 in the differentiation of osteoblast was increased, thereby promoting the differentiation of osteoblast.

Association of Bone Density Monitoring in Routine Clinical Practice With Anti-Osteoporosis Medication Use and Incident Fractures: A Matched Cohort Study

Routine bone mineral density (BMD) monitoring of individuals during the initial 5 years of anti-osteoporosis treatment is controversial. Using a registry-based cohort from the Province of Manitoba, Canada, we compared anti-osteoporosis medication use and fracture outcomes in women with versus without BMD monitoring receiving anti-osteoporosis medication. We identified 4559 women aged 40 years and older receiving anti-osteoporosis therapy with serial BMD testing (monitoring) within 5 years (mean interval 3.2 years) and 4559 propensity score-matched women without BMD monitoring. We assessed anti-osteoporosis medication use over 5 years from a population-based retail pharmacy database. Incident fractures to 10 years from health services data. During median 10 years observation, 1225 (13.4%) women developed major osteoporotic fracture, including 382 (4.2%) with hip fractures. Monitored women had significantly better fracture-free survival for major osteoporotic fracture (p = 0.040; 10-year cumulative risk 1.9% lower, 95% confidence interval [CI] 0.3-3.6%) and hip fracture ( p = 0.001; 10-year cumulative risk 1.8% lower, 95% CI 0.7-2.8%) compared with women who were not monitored. Hazard ratios (HRs) were significantly lower in monitored versus not monitored women for major osteoporotic fracture (HR = 0.89, 95% CI 0.80-0.98) and hip fracture (HR = 0.74, 95% CI 0.63-0.87). Days of medication use, medication persistence ratio, and treatment switching over 5 years were greater in monitored versus not monitored women. At the end of 5 years, more women in the monitored group persisted on treatment and more switched treatment, with switching behavior associated with an observed interval reduction in BMD. In conclusion, our findings suggest a possible role for BMD monitoring after initiating anti-osteoporosis therapy in the routine clinical practice setting. © 2019 American Society for Bone and Mineral Research.